Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06889766 |
| Title | Evaluation of the Feasibility and Safety of Immunotherapy Based on Autologous T Lymphocytes Genetically Modified to Specifically Recognize the Tumor Antigen NY-ESO-1, in HLA-A*0201 and/or HLA-A*0205 Positive Patients With Advanced Melanoma or Sarcoma Expressing NY-ESO-1 (LauT1) |
| Acronym | LauT1 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Centre Hospitalier Universitaire Vaudois |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | CHE |